Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges (2010 - 2026)

Ligand Pharmaceuticals has disclosed Amortization of Deferred Charges across 15 years of filings, most recently posting $803000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $803000.0, up 490.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 251.86% YoY), and the FY2025 annual result was $1.3 million, up 161.93% from the prior year.
• Amortization of Deferred Charges came in at $803000.0 for Q1 2026 at Ligand Pharmaceuticals, up from $565000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $803000.0 in Q1 2026 to a low of $81000.0 in Q4 2023.
• The 5-year median for Amortization of Deferred Charges is $129500.0 (2024), against an average of $219500.0.
• Across the five-year window, Amortization of Deferred Charges plunged 97.52% in 2022 and soared 490.44% in 2026, its largest moves.
• Ligand Pharmaceuticals' Amortization of Deferred Charges stood at $95000.0 in 2022, then declined by 14.74% to $81000.0 in 2023, then surged by 112.35% to $172000.0 in 2024, then surged by 228.49% to $565000.0 in 2025, then soared by 42.12% to $803000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $803000.0 (Q1 2026), $565000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.